Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF

Virology

Volumn 290, Issue 1, 2001, Pages 74-82

  Raviprakash, Kanakatte ^a,b   Marques, Ernesto ^c   Ewing, Dan ^a   Lu, Yang ^c   Phillips, Irving ^a   Porter, Kevin R ^a   Kochel, Tadeusz J ^a   August, Thomas J ^c   Hayes, Curtis G ^a   Murphy, Gerald S ^a,b  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dengue; DNA vaccine; GM CSF; LAMP; Lysosome targeting; Neutralizing antibody

Indexed keywords

DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CYTOPLASM; DENGUE; DENGUE VIRUS; EVALUATION; HYPOTHESIS; IMMUNIZATION; IMMUNOGENICITY; LYSOSOME; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN LOCALIZATION; VACCINATION; VIRUS NEUTRALIZATION;

DENGUE VIRUS; DENGUE VIRUS TYPE 1; DENGUE VIRUS TYPE 2; MACACA MULATTA; MURINAE;

EID: 0035841643     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2001.1136     Document Type: Article

References (42)

1. Evaluation of Vero cell lysate antigen for the ELISA of flaviviruses
2. Japanese encephalitis and dengue vaccines
3. Yellow fever vaccines
4. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus
5. Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue
6. Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons
7. Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and nonstructural proteins: Evidence of priming and partial protection
8. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans
9. The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1
10. Emergence of epidemic dengue/dengue hemorrhagic fever as a public health problem in the Americas
11. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles
12. Pathogenesis of dengue: Challenges to molecular biology
13. Immunogenic peptides bind to class II MHC molecules in an early lysosomal compartment
14. An improved plasmid DNA expression vector for direct injection into skeletal muscle
15. Cancer gene therapy using plasmid DNA: Purification of DNA for human clinical trials
16. Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain)
17. Modulation of amplitude and direction of in vivo immune responses by co-adminstration of cytokine gene expression cassettes with DNA immunogens
18. MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells
19. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants
20. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice
21. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys
22. Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes
23. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice
24. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
25. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers
26. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
27. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-speceific immunoglobulin G
28. Major histocompatibility complex class II compartments in human B lymphoblastoid cells are distinct from early endosomes
29. Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus
30. Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses
31. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein
32. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques
33. Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells
34. The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway
35. A plaque reduction test for dengue virus neutralizing antibodies
36. Dengue viruses
37. Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge
38. Transport of peptide-MHC class II complexes in developing dendritic cells
39. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens
40. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines
41. Genetic vaccines - A revolution in vaccinology?